5 results
To evaluate the efficacy and safety of BIBF 1120 in HCC patients without prior systemic treatment as compared to Sorafenib.
To evaluate whether doxepin hydrochloride 5% cream is more effective in reducing pruritus in burn patients than standard treatment (clemastine).
to evaluate whether Doxepin hydrochloride 5% cream versus a placebo cream significantly reduces pruritus in burn patients by comparing itch scores.
The revised aims of the SORCE trial are:1. Does up to three years of treatment with sorafenib increase DFS compared with placebo: a comparison of Arm C vs Arm A2. If the answer to question (i) is yes, does one year of sorafenib (Arm B) increase DFS…
To study the correlation between EMG values of the pelvic floor and functional outcomes of patients who has been treated for rectal cancer in the period January 2014 till December 2018.